SIX
Every company in the roster listed on SIX.
Every company in the roster listed on SIX.
4 of 4 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Cosmo N.V.COPN · SIX | 2 assets: 2 approved | Approved assets only | None on record | — | — | — | — |
GaldermaGALD · SIX | 1 asset: 1 approved | Approved assets only | Dec 2026nemolizumab · Phase 2 | — | — | — | — |
Idorsia PharmaceuticalsIDIA · SIX | 1 asset: 1 approved | Approved assets only | None on record | — | $119MMar 2026 | Ended Oct 2026 | $123M |
Sandoz Group AGSDZ · SIX | 9 assets: 9 approved | Approved assets only | None on record | — | — | — | — |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.